COMP <GO>
SUPN vs JNJ // ENTERPRISE SCALE & MARKET CAP
Supernus Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SUPN 4
— JNJ 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
market-cap
$2.43B
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 67.90% | +21.70 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 25.50% | -30.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 2.97% | -1.08 | JNJ | /fcf-yield <GO> |
| Operating Margin | -8.70% | 34.70% | -43.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 28.50% | -33.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 6.00% | +2.60 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 5.59 | -0.75 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | SUPN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 60.4 | -9.36 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | SUPN | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.43B | $662.49B | -$660.06B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | JNJ REV | SUPN GROSS % | JNJ GROSS % | SUPN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $94.19B | 89.6% | 67.9% | $46.0M | $19.70B |
| FY 2024 | $661.8M | $88.82B | 88.2% | 69.1% | $171.2M | $19.84B |
| FY 2023 | $607.5M | $85.16B | 44.0% | 44.0% | $83.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
JNJ // BETA 1.08